News Releases

October 2018

October 26, 2018 10/26/2018 Takeda Announces Execution of Senior Short Term Loan Facility Agreement and Subordinated Syndicated Loan Agreement and Second Amendment to Bridge Credit Agreement in Connection with Proposed Acquisition of Shire plc

October 25, 2018 10/25/2018 Takeda to Highlight Data in Hodgkin Lymphoma During the 11th International Symposium on Hodgkin Lymphoma

October 22, 2018 10/22/2018 Investigational Subcutaneous Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Ulcerative Colitis

October 19, 2018 10/19/2018 Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib)

October 18, 2018 10/18/2018 Takeda receives clearance from the Japan Fair Trade Commission for the proposed acquisition of Shire plc

October 1, 2018 10/1/2018 Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial

September 2018

September 28, 2018 9/28/2018 Takeda and Lundbeck Submit New Drug Application (NDA) for Vortioxetine in Japan for the Treatment of Major Depressive Disorder (MDD)

September 28, 2018 9/28/2018 Takeda Establishes Record Date for the Extraordinary General Meeting of Shareholders

September 25, 2018 9/25/2018 Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial